Lacerta Bio is a business development consultancy specializing in identifying, assessing, negotiating, and closing licensing and partnership opportunities for the pharmaceutical, biotechnology, and drug delivery industries.

We also work with and support internal business development teams with market research, competitive intelligence, financial modeling, and other support services.

In November, 2014, we announced a merger with Copenhagen-based Ventac Partners. The combination of Lacerta Bio and Ventac Partners will dramatically increase the types of services we can offer our clients, as well as expand our geographic reach.

If you need assistance finding or assessing business development and/or partnership opportunities, contact us at info@lacertabio.com.


Current Projects

China: Opportunities to Access Partnerships and Capital  
Posted on Feb 14, 2015

Article

Would You Like To Expand Your Business Into China? Or Perhaps You Seek An Investor or Development Partner? China is a large and growing opportunity for Western life science companies, as: Life Science in China is Booming – China’s life science industry has been growing at more than 20%+ per year, and is expect to

  Read More»

Seeking Product Acquisition Opportunities  
Posted on Jan 21, 2015

Article

Our client is seeking product acquisition opportunities, according to the following criteria: Geography – Primarily US, but Canada and selected other European Territories. Global rights are possible for the right product. Therapeutic Areas – Gastroenterology, Pain Management, Oncology Supportive Care, and Selected Orphan Diseases. Dermatology products would also be considered. Stage of Development – Phase

  Read More»

Seeking Acquisitions - Profitable US Companies  
Posted on Jan 21, 2015

Article

A European pharmaceutical company is seeking acquisition opportunities in the US. Their general criteria are as follows: Annual Revenue – They prefer companies generating $5 million to $40 million in prescription product sales EBITDA – Positive. That is, no turnaround situations. Therapeutic Areas – Preference for companies seeking products in Pain Management, Dermatology, GI, Oncology

  Read More»

Our Latest Article

What Pharma Want: Comments On Article 
Posted on May 11, 2015

Article

 

Earlier this month, our friends at Biotech and Money published a transcript from a panel discussion at their London 2015 congress

The discussion was quite interesting, and we encourage readers to check it out. 

The topic for this discussion was whether or not M&A is being brought earlier and earlier into the R&D lifecycle. And, if so, what are the implications from the perspectives of a biotech company, a big pharma company, and a VC. 

Here are a few ideas from the discussion which caught our eye:

Earlier TrackingKevin Johnson from Index Ventures noted that companies in their portfolio are “…tracked far earlier…and tracked fairly aggressively.” This is interesting because if you are a biotech with a novel asset that is of potential interest to big pharma, then you should be preparing for a trade sale essentially from Day One. 

This implies, for example, having corporate non-confidential and confidential presentations and data prepared and well-organized, having a communications plan for management and Board members, etc. 

This also suggests that companies who have clear search criteria and strategies have scouting networks and systems which can spot and track nascent companies for future transactions. No longer are the scouts waiting for opportunities to come to them, especially in therapeutic areas where competition for novel assets is high, such as immuno-oncology. 

So be prepared…

CVRs not easy for GSK – Beverley Carr from GSK noted that transactions which include contingent value rights are “…not so easy for GSK, which is a function of us being a UK accounting company.” Now we’re not experts in international accounting, but one would think that the smart City accountants and lawyers would have figured this problem out, no?

Tail Wagging The Dog –  Should Sales and Marketing drive the BD wish list, or should BD simply find the best assets and have Sales and Marketing respond to the pipeline? Similarly, should Commercial drive R&D strategy? To put it another way, should you license your prized asset to a company who has recently exited that therapeutic area?

The debate amongst the panelists was quite interesting. We tend to agree with the notion that it’s far easier to build a sales and marketing team than it is to find a great asset. But we certainly understand the other side of the argument was well. 


Latest Posts

Preparing for #BIO2015 in Philadelphia…Already? 
Posted on Apr 27, 2015

  We’ve started preparing for the BIO convention in Philadelphia in June. Preparing? Already?  Yes.  Why start now? We’ll give you three reasons: New Partnering Interface – BIO has unveiled a brand new interface for the One-on-One Partnering system. Everything is new, and the old profiles will NOT automatically populate the new system. You will have

Independent Consultants Wanted 
Posted on Apr 27, 2015

  Are you an independent consultant? Are you looking for a new platform or channel to help grow and expand your practice? Why not join us! Lacerta Bio is looking for independent consultants to both work on projects and to form new biotech companies. Projects – We regularly need expert help in a few key

Employee-Free Biotechs: A Virtual Panacea? 
Posted on Apr 13, 2015

  Last week Reuters published an article summarizing the “virtual” biotech business model. It was a strange article, considering that this is not a new approach. Indeed, we wrote about this model as far back as 2011. According to Reuters, The new model has grabbed attention as venture capitalists strive to improve returns in a notoriously

Google Plus   Facebook   Twitter
Powered By : Supra International Inc.